Health and Me

Tanya Dutt

Common Heart Attack Pills May Not Be Safe For Women, New Study Shares Warning

Latest research is challenging decades of established cardiac treatment, revealing that a commonly prescribed class of heart attack medications—beta-blockers—may not benefit most patients and could even pose significant risks for women. This groundbreaking finding, presented in major cardiology journals and conferences, underscores the urgent need for sex-specific approaches in cardiovascular care.

Beta-blockers have been a "heart" of heart attack management for decades, prescribed to help lower heart rate, reduce blood pressure, and decrease the heart’s oxygen demand. Their intended effect is to prevent further cardiac events and improve survival. However, new findings indicate that these benefits are not universal.

According to the REBOOT trial, women who suffered heart attacks but retained normal heart function measured by a left ventricular ejection fraction above 50%, experienced significantly higher risks when treated with beta-blockers. These women were more likely to be hospitalized for heart failure, experience another heart attack, and, alarmingly, nearly three times more likely to die than their counterparts not on the medication. The risk increased with higher doses.

“This is a pivotal moment in cardiology,” said Dr. Valentin Fuster, president of Mount Sinai Fuster Heart Hospital in New York City and director of Spain’s National Center for Cardiovascular Investigation. “These findings will reshape international clinical guidelines and emphasize the importance of sex-specific treatment strategies for cardiovascular disease.”

<h2>Why Women Respond Differently to Beta-Blockers?</h2>

The heart disease profile differs markedly between men and women, a factor long overlooked in clinical research. Men typically suffer from plaque buildup in major arteries, often presenting with classic chest pain during a heart attack. Women, on the other hand, more frequently experience issues in the smaller blood vessels of the heart and may exhibit atypical symptoms such as shortness of breath, indigestion, or back pain.

Historically, cardiovascular studies have largely focused on male patients, delaying recognition of these sex-based differences in presentation and treatment response. The new research highlights how generalized treatment protocols may inadvertently harm women while offering minimal benefit to those with normally functioning hearts.

<h3>The REBOOT Trial and Key Findings</h3>

The REBOOT study followed 8,505 men and women across 109 hospitals in Spain and Italy for nearly four years. Patients included in the trial all had a left ventricular ejection fraction above 40%, meaning their hearts were pumping normally. The trial specifically assessed whether beta-blockers provided benefits in preventing secondary cardiac events.

While men and women with mild heart dysfunction—ejection fraction between 40% and 50%—did see some benefit from beta-blockers, women with normal heart function did not. In this subgroup, beta-blocker therapy was associated with worse outcomes, including increased hospitalization and mortality rates.

“These results underscore the need to differentiate treatment plans based on both sex and heart function,” explained lead study author Dr. Borja Ibáñez of Madrid’s National Center for Cardiovascular Investigation. “The majority of patients following a first heart attack actually fall into this normal heart function category, meaning current beta-blocker prescriptions could be largely unnecessary, and in some cases, harmful.”

<h3>Heart Attacks Among Women: Conflicting Evidence from Other Trials</h3>

Interestingly, not all recent trials agree. The BETAMI–DANBLOCK study, which included 5,574 participants in Norway and Denmark, demonstrated that beta-blockers reduced the risk of death or major adverse cardiovascular events by 15%. Differences between the studies may stem from variations in patient age, beta-blocker type, and baseline heart function, but the critical takeaway remains, treatment is not one-size-fits-all.

Dr. Dan Atar of the University of Oslo noted, “While beta-blockers remain essential for patients with significant heart damage, for those with normal function, particularly women, the risk-benefit balance is much less favorable.”

<h2>What Are The Implications for Women’s <span rel="noindex">Heart Health</span>?</h2>

These findings are a clarion call for more gender-sensitive approaches in cardiology. Women account for nearly half of all heart attack cases, yet research and treatment protocols have historically centered on male physiology. The revelation that beta-blockers may pose a serious risk for women with normal heart function challenges long-held assumptions and emphasizes the importance of personalized medicine.

Experts urge women who have experienced a heart attack to discuss their treatment options thoroughly with their cardiologist, particularly if prescribed beta-blockers. Monitoring heart function via left ventricular ejection fraction and considering alternative medications may be safer in many cases.

Beta-blockers function by blocking the effects of epinephrine and norepinephrine, calming the heart and reducing its workload. While this can be lifesaving for patients with compromised heart function, the drugs may unnecessarily suppress heart activity in individuals whose hearts are already pumping normally. This over-suppression could explain the increased hospitalization and mortality rates observed in women with healthy ejection fractions.

The implications of these studies extend beyond beta-blockers. They highlight a broader need for sex-specific research and personalized medicine in cardiology. Cardiovascular disease remains the leading cause of death globally, and addressing sex-based differences in treatment is critical to improving outcomes for all patients.

“The time for generic prescriptions is over,” said Dr. Fuster. “Cardiology must recognize that men and women respond differently to medications and that clinical guidelines must reflect these differences.”

In light of these findings, international guidelines may soon be revised to limit beta-blocker use to patients with reduced heart function or those at high risk of arrhythmias. Women with normal ejection fractions should have alternative treatment strategies considered to minimize potential harm.

Pharmaceutical companies producing beta-blockers, including Pfizer, Novartis, Teva, and Sun Pharma, may also need to review dosing recommendations and safety protocols to align with emerging evidence.

The new research into beta-blockers after heart attacks challenges a decades-old assumption in cardiology and emphasizes the importance of personalized, sex-specific treatment. For women with normal heart function, these commonly prescribed medications may offer no benefit and even increase risks. As the medical community revises guidelines and treatment protocols, patients and healthcare providers alike must prioritize individualized approaches to ensure the safest and most effective care.

Health Conditions A-Z

health

heart health

beta blockers

heart attack treatment

women heart health

cardiovascular risk

myocardial infarction

sex specific medicine

cardiac medication safety

Cardiologist Says He Would Never Buy These 10 Foods 'After 20 Years Of Treating Heart Diseases'

Deadly Flesh-Eating Bacteria Kills Two Oysters Kill Two: Is Climate Change Making Infection Worse?

Health News

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

Immune-Boosting Foods To Have During Rainy Season

Potato Based Dishes You For Week-Long Meal Prep

Latest research is challenging decades of established cardiac treatment, revealing that a commonly prescribed class of heart attack medications—beta-blockers—may not benefit most patients and could even pose significant risks for women. This groundbreaking finding, presented in major cardiology journals and conferences, underscores the urgent need for sex-specific approaches in cardiovascular care.Beta-blockers have been a "heart" of heart attack management for decades, prescribed to help lower heart rate, reduce blood pressure, and decrease the heart’s oxygen demand. Their intended effect is to prevent further cardiac events and improve survival. However, new findings indicate that these benefits are not universal.According to the REBOOT trial, women who suffered heart attacks but retained normal heart function measured by a left ventricular ejection fraction above 50%, experienced significantly higher risks when treated with beta-blockers. These women were more likely to be hospitalized for heart failure, experience another heart attack, and, alarmingly, nearly three times more likely to die than their counterparts not on the medication. The risk increased with higher doses.“This is a pivotal moment in cardiology,” said Dr. Valentin Fuster, president of Mount Sinai Fuster Heart Hospital in New York City and director of Spain’s National Center for Cardiovascular Investigation. “These findings will reshape international clinical guidelines and emphasize the importance of sex-specific treatment strategies for cardiovascular disease.”Why Women Respond Differently to Beta-Blockers?The heart disease profile differs markedly between men and women, a factor long overlooked in clinical research. Men typically suffer from plaque buildup in major arteries, often presenting with classic chest pain during a heart attack. Women, on the other hand, more frequently experience issues in the smaller blood vessels of the heart and may exhibit atypical symptoms such as shortness of breath, indigestion, or back pain.Historically, cardiovascular studies have largely focused on male patients, delaying recognition of these sex-based differences in presentation and treatment response. The new research highlights how generalized treatment protocols may inadvertently harm women while offering minimal benefit to those with normally functioning hearts.The REBOOT Trial and Key FindingsThe REBOOT study followed 8,505 men and women across 109 hospitals in Spain and Italy for nearly four years. Patients included in the trial all had a left ventricular ejection fraction above 40%, meaning their hearts were pumping normally. The trial specifically assessed whether beta-blockers provided benefits in preventing secondary cardiac events.While men and women with mild heart dysfunction—ejection fraction between 40% and 50%—did see some benefit from beta-blockers, women with normal heart function did not. In this subgroup, beta-blocker therapy was associated with worse outcomes, including increased hospitalization and mortality rates.“These results underscore the need to differentiate treatment plans based on both sex and heart function,” explained lead study author Dr. Borja Ibáñez of Madrid’s National Center for Cardiovascular Investigation. “The majority of patients following a first heart attack actually fall into this normal heart function category, meaning current beta-blocker prescriptions could be largely unnecessary, and in some cases, harmful.”Heart Attacks Among Women: Conflicting Evidence from Other TrialsInterestingly, not all recent trials agree. The BETAMI–DANBLOCK study, which included 5,574 participants in Norway and Denmark, demonstrated that beta-blockers reduced the risk of death or major adverse cardiovascular events by 15%. Differences between the studies may stem from variations in patient age, beta-blocker type, and baseline heart function, but the critical takeaway remains, treatment is not one-size-fits-all.Dr. Dan Atar of the University of Oslo noted, “While beta-blockers remain essential for patients with significant heart damage, for those with normal function, particularly women, the risk-benefit balance is much less favorable.”What Are The Implications for Women’s Heart Health?These findings are a clarion call for more gender-sensitive approaches in cardiology. Women account for nearly half of all heart attack cases, yet research and treatment protocols have historically centered on male physiology. The revelation that beta-blockers may pose a serious risk for women with normal heart function challenges long-held assumptions and emphasizes the importance of personalized medicine.Experts urge women who have experienced a heart attack to discuss their treatment options thoroughly with their cardiologist, particularly if prescribed beta-blockers. Monitoring heart function via left ventricular ejection fraction and considering alternative medications may be safer in many cases.How Do Beta-Blockers Work?Beta-blockers function by blocking the effects of epinephrine and norepinephrine, calming the heart and reducing its workload. While this can be lifesaving for patients with compromised heart function, the drugs may unnecessarily suppress heart activity in individuals whose hearts are already pumping normally. This over-suppression could explain the increased hospitalization and mortality rates observed in women with healthy ejection fractions.The implications of these studies extend beyond beta-blockers. They highlight a broader need for sex-specific research and personalized medicine in cardiology. Cardiovascular disease remains the leading cause of death globally, and addressing sex-based differences in treatment is critical to improving outcomes for all patients.“The time for generic prescriptions is over,” said Dr. Fuster. “Cardiology must recognize that men and women respond differently to medications and that clinical guidelines must reflect these differences.”In light of these findings, international guidelines may soon be revised to limit beta-blocker use to patients with reduced heart function or those at high risk of arrhythmias. Women with normal ejection fractions should have alternative treatment strategies considered to minimize potential harm.Pharmaceutical companies producing beta-blockers, including Pfizer, Novartis, Teva, and Sun Pharma, may also need to review dosing recommendations and safety protocols to align with emerging evidence.The new research into beta-blockers after heart attacks challenges a decades-old assumption in cardiology and emphasizes the importance of personalized, sex-specific treatment. For women with normal heart function, these commonly prescribed medications may offer no benefit and even increase risks. As the medical community revises guidelines and treatment protocols, patients and healthcare providers alike must prioritize individualized approaches to ensure the safest and most effective care.

beta-blockers: common heart attack pills may not be safe for women, new study shares warning

NHS Launches Free Chickenpox Vaccine: How Vaccinations Can Help Keep Kids In School And Reduce Absenteeism

NHS Rolls Out Free Chickenpox Vaccination For Kids Across England Starting Next Year

UK Children To Get Chickenpox Vaccine On NHS: Why It Is A Lifesaver Vaccine

uk children to get chickenpox vaccine on nhs: why it is a lifesaver vaccine

Shingles Vaccines Now Available For 18+ People With Weak Immune Systems - How Long Does The Vaccine Last?

shingles vaccines now available for 18+ people with weak immune systems - how long does the vaccine last?

'Act Now To Protect Yourself ', Warns AMA As Whooping Cases Hit Decades-High, Calls For Vaccinations

'act now to protect yourself ', warns ama as whooping cases hit decades-high, calls for vaccinations

Health & Wellness

Study Reveals Why Autism in Over-40s Rarely Gets Recognised

study reveals why autism in over-40s rarely gets recognised

From January 2026, NHS England will offer free chickenpox vaccinations to eligible children, a move that promises to reduce illness, prevent hospital admissions, and minimize disruption to both children’s education and parental work schedules.

This historic addition to the childhood immunisation programme will protect approximately half a million children each year, offering not only medical protection but also supporting children’s academic performance and social development by keeping them in school.

Chickenpox, caused by the varicella zoster virus, is highly contagious. While often considered a mild childhood illness, it can sometimes lead to severe complications, including bacterial infections, pneumonia, inflammation of the brain, stroke, and, in rare cases, death. Adults who have not previously had chickenpox are at higher risk of serious illness. After initial infection, the virus remains dormant and can reactivate later in life as shingles, which is why the UK has maintained a shingles vaccination programme for older adults since 2013.

Dr. Gayatri Amirthalingam, Deputy Director of Immunisation at the UK Health Security Agency, emphasised that while chickenpox is often viewed as a minor disease, vaccination can be life-saving for children at risk of severe complications. "This programme will have a really positive impact on children’s health and also reduce missed nursery and school days," she said.

<h2>How Vaccination Supports School Attendance and Child Development?</h2>

One of the less-discussed benefits of the chickenpox vaccine is its impact on children’s education and social growth. School absenteeism due to illness disrupts learning, affects participation in extracurricular activities, and can hinder social interactions with peers. By preventing chickenpox, the MMRV vaccine ensures children remain in school, contributing to better academic performance and stable social development.

For working parents, the benefits are equally significant. Childhood chickenpox often forces parents to take time off work, affecting productivity. Research suggests that chickenpox in the UK results in an estimated £24 million in lost income annually, with an additional £15 million spent by the NHS on treatments. Keeping children healthy and in school not only improves their educational experience but also reduces the economic burden on families and public health systems.

Eligible children will receive a combined measles, mumps, rubella, and varicella (MMRV) vaccine during routine GP appointments. This approach ensures high vaccine uptake while providing protection against multiple infectious diseases. The programme is informed by the Joint Committee on Vaccination and Immunisation (JCVI), which reviewed evidence showing the impact of severe chickenpox on children’s health, hospital admissions, and associated costs.

Private varicella vaccines currently cost around £150 for two doses, but the NHS rollout will make the vaccine free for eligible children, ensuring equitable access.

<h2>Lessons in Childhood Immunisation</h2>

Countries including the United States, Canada, Germany, and Australia have already incorporated the chickenpox vaccine into their childhood immunisation schedules, seeing dramatic reductions in incidence and related hospitalisations. In the US alone, CDC data shows that over 25 years, vaccination prevented 91 million cases, 238,000 hospital admissions, and 2,000 deaths. England’s adoption of the MMRV vaccine aligns with these global best practices, offering children the safest and most effective protection.

<h3>Protecting Vulnerable Populations and Building Community Immunity</h3>

Beyond individual protection, the vaccine helps shield vulnerable populations such as pregnant women and immunocompromised patients. By reducing the circulation of the varicella virus, community immunity is strengthened, limiting outbreaks and preventing infections in children who cannot be vaccinated due to medical conditions.

<h3>Integration With Broader Health Initiatives</h3>

The chickenpox vaccine rollout is part of the government’s “Plan for Change,” aimed at raising the healthiest generation of children ever and shifting NHS focus from treatment to prevention. It complements other measures in the 10-Year Health Plan, such as free school meals, mental health services, and dental care. Additionally, the Department for Education’s Best Start Family Hubs will further support families, ensuring more children receive the healthiest possible start in life.

<h3>Moving Beyond “Chickenpox Parties”</h3>

Historically, some parents exposed children to chickenpox intentionally through “chickenpox parties” to develop natural immunity. Today, evidence-based immunisation replaces these practices with safe, effective, and preventative healthcare. Parents will be contacted by GP surgeries to schedule MMRV vaccinations, which will follow age-specific clinical guidance to ensure maximum effectiveness.

<h2>What Are The Long-Term Benefits of Free Vaccination for Children?</h2>

By preventing chickenpox, children experience fewer school absences, maintain consistent peer interactions, and avoid the stress and discomfort of illness. This creates a foundation for better academic performance, stronger social bonds, and overall well-being. The reduction in parental work disruption also contributes to family stability and societal productivity.

Amanda Doyle, NHS England’s National Director for Primary Care and Community Services, highlighted the significance of the rollout, “This is a very welcome moment for families as the NHS prepares to offer a vaccine to protect children against chickenpox for the first time. It complements other routine jabs that safeguard against serious illness and supports children in staying healthy and in school.”

The NHS chickenpox vaccination programme marks a proactive step in public health, combining disease prevention with educational and social benefits. Protecting half a million children each year, it ensures not only reduced illness and hospitalisation but also supports uninterrupted schooling, positive social development, and stronger family and community health. England’s children are poised to become the healthiest and most resilient generation yet, thanks to this strategic immunisation initiative.

nhs chickenpox vaccine

free childhood vaccination uk

mmrv vaccine rollout

chickenpox protection england

childhood immunisation nhs

prevent chickenpox complications

uk vaccination programme

From January 2026, NHS England will offer free chickenpox vaccinations to eligible children, a move that promises to reduce illness, prevent hospital admissions, and minimize disruption to both children’s education and parental work schedules.This historic addition to the childhood immunisation programme will protect approximately half a million children each year, offering not only medical protection but also supporting children’s academic performance and social development by keeping them in school.Chickenpox, caused by the varicella zoster virus, is highly contagious. While often considered a mild childhood illness, it can sometimes lead to severe complications, including bacterial infections, pneumonia, inflammation of the brain, stroke, and, in rare cases, death. Adults who have not previously had chickenpox are at higher risk of serious illness. After initial infection, the virus remains dormant and can reactivate later in life as shingles, which is why the UK has maintained a shingles vaccination programme for older adults since 2013.Dr. Gayatri Amirthalingam, Deputy Director of Immunisation at the UK Health Security Agency, emphasised that while chickenpox is often viewed as a minor disease, vaccination can be life-saving for children at risk of severe complications. "This programme will have a really positive impact on children’s health and also reduce missed nursery and school days," she said.How Vaccination Supports School Attendance and Child Development?One of the less-discussed benefits of the chickenpox vaccine is its impact on children’s education and social growth. School absenteeism due to illness disrupts learning, affects participation in extracurricular activities, and can hinder social interactions with peers. By preventing chickenpox, the MMRV vaccine ensures children remain in school, contributing to better academic performance and stable social development.For working parents, the benefits are equally significant. Childhood chickenpox often forces parents to take time off work, affecting productivity. Research suggests that chickenpox in the UK results in an estimated £24 million in lost income annually, with an additional £15 million spent by the NHS on treatments. Keeping children healthy and in school not only improves their educational experience but also reduces the economic burden on families and public health systems.NHS Evidence-Based RolloutEligible children will receive a combined measles, mumps, rubella, and varicella (MMRV) vaccine during routine GP appointments. This approach ensures high vaccine uptake while providing protection against multiple infectious diseases. The programme is informed by the Joint Committee on Vaccination and Immunisation (JCVI), which reviewed evidence showing the impact of severe chickenpox on children’s health, hospital admissions, and associated costs.Private varicella vaccines currently cost around £150 for two doses, but the NHS rollout will make the vaccine free for eligible children, ensuring equitable access.Lessons in Childhood ImmunisationCountries including the United States, Canada, Germany, and Australia have already incorporated the chickenpox vaccine into their childhood immunisation schedules, seeing dramatic reductions in incidence and related hospitalisations. In the US alone, CDC data shows that over 25 years, vaccination prevented 91 million cases, 238,000 hospital admissions, and 2,000 deaths. England’s adoption of the MMRV vaccine aligns with these global best practices, offering children the safest and most effective protection.Protecting Vulnerable Populations and Building Community ImmunityBeyond individual protection, the vaccine helps shield vulnerable populations such as pregnant women and immunocompromised patients. By reducing the circulation of the varicella virus, community immunity is strengthened, limiting outbreaks and preventing infections in children who cannot be vaccinated due to medical conditions.Integration With Broader Health InitiativesThe chickenpox vaccine rollout is part of the government’s “Plan for Change,” aimed at raising the healthiest generation of children ever and shifting NHS focus from treatment to prevention. It complements other measures in the 10-Year Health Plan, such as free school meals, mental health services, and dental care. Additionally, the Department for Education’s Best Start Family Hubs will further support families, ensuring more children receive the healthiest possible start in life.Moving Beyond “Chickenpox Parties”Historically, some parents exposed children to chickenpox intentionally through “chickenpox parties” to develop natural immunity. Today, evidence-based immunisation replaces these practices with safe, effective, and preventative healthcare. Parents will be contacted by GP surgeries to schedule MMRV vaccinations, which will follow age-specific clinical guidance to ensure maximum effectiveness.What Are The Long-Term Benefits of Free Vaccination for Children?By preventing chickenpox, children experience fewer school absences, maintain consistent peer interactions, and avoid the stress and discomfort of illness. This creates a foundation for better academic performance, stronger social bonds, and overall well-being. The reduction in parental work disruption also contributes to family stability and societal productivity.Amanda Doyle, NHS England’s National Director for Primary Care and Community Services, highlighted the significance of the rollout, “This is a very welcome moment for families as the NHS prepares to offer a vaccine to protect children against chickenpox for the first time. It complements other routine jabs that safeguard against serious illness and supports children in staying healthy and in school.”The NHS chickenpox vaccination programme marks a proactive step in public health, combining disease prevention with educational and social benefits. Protecting half a million children each year, it ensures not only reduced illness and hospitalisation but also supports uninterrupted schooling, positive social development, and stronger family and community health. England’s children are poised to become the healthiest and most resilient generation yet, thanks to this strategic immunisation initiative.

nhs rolls out free chickenpox vaccination for kids across england starting next year

New York City Declares Harlem Legionnaire’s Disease Outbreak Over: Here's What Killed 7 People

new york city declares harlem legionnaire’s disease outbreak over: here's what killed 7 people

Australia is facing its largest whooping cough outbreak in more than three decades, with medical leaders sounding an urgent alarm: vaccination is the only reliable shield. Whooping cough, or pertussis, is not a new disease, but it is making a dramatic comeback. In 2024, more than 57,000 cases were reported across Australia the highest number since 1991. And the wave has not slowed. In South Australia, early 2025 data show over 1,000 infections — more than ten times higher than the same period last year.

The national disease surveillance dashboard reports nearly 19,000 cases already in 2025, with hotspots including Queensland, South Australia, and Western Australia’s Kimberley region. Doctors say this is now Australia’s most significant and long-lasting pertussis outbreak in decades.

Pertussis is caused by the bacterium Bordetella pertussis. It spreads easily through coughs and sneezes, thriving in close-contact settings such as households and schools. For most adults, it causes weeks of relentless coughing that disrupts sleep, work, and quality of life. But for infants — especially those too young to be vaccinated it can be life-threatening.

Newborns can develop severe respiratory distress, pneumonia, and even brain damage from prolonged oxygen deprivation during coughing fits. Globally, the World Health Organization estimates that pertussis kills tens of thousands of children every year, most of them under six months old.

The Australian Medical Association (AMA) has issued a clear warning: complacency is dangerous. AMA President Dr. Danielle McMullen described the outbreak as “extremely concerning,” citing both the sheer scale of cases and the drop in vaccination coverage.

“We can’t afford to be complacent,” Dr. McMullen said. “Each year, thousands of lives are lost to respiratory diseases like whooping cough — and we all have a role to play in preventing their spread. Vaccination remains our most powerful defence.”

<h2>Why Pregnancy Vaccination is Crucial?</h2>

One of the AMA’s strongest messages is directed at expectant mothers. A pertussis-containing vaccine is recommended during every pregnancy, ideally between 20 and 32 weeks. This approach allows protective antibodies to pass from mother to baby through the placenta, shielding the newborn during the critical first weeks of life.

“Maternal vaccination creates antibodies which are passed to the unborn baby and protect them in their first days and weeks of life,” Dr. McMullen explained. “But it doesn’t stop there — ensuring family members and other caregivers are also vaccinated helps create a protective cocoon around infants.”

This cocooning strategy reduces the risk that parents, grandparents, siblings, or caregivers will transmit the infection to newborns who are too young to complete their first immunization schedule.

<h3>Vaccines Are Free and Accessible</h3>

In Australia, whooping cough vaccines are free for all pregnant women under the National Immunisation Program. Parents are also encouraged to keep their children’s vaccines up to date, particularly during the first six months, when infants are most vulnerable.

For adults, boosters are recommended every 10 years, especially for anyone living with or caring for babies. General practitioners and pharmacies can check vaccination records and provide catch-up doses when needed.

<h3>Falling Vaccination Rates and Rising Cases</h3>

Part of what makes this outbreak alarming is its timing. Australia has not met its childhood vaccination targets in several regions, and vaccine hesitancy has crept upward in recent years. This leaves pockets of communities vulnerable, creating fertile ground for pertussis to spread.

The AMA warns that failing to address this could undo decades of progress in reducing serious childhood diseases. “Getting vaccinated is one of the simplest and most effective ways you can protect your loved ones and your community,” Dr. McMullen said.

Australia has seen waves of whooping cough before. The last major epidemic peaked in 2011 with over 38,000 cases. But today’s surge is different in scale, surpassing even that crisis and persisting longer. Globally, other countries have also seen cyclical rises in pertussis, underscoring that this is not just an Australian problem.

The key difference between a contained outbreak and a devastating one is vaccination coverage. Experts point to herd immunity thresholds: when enough people are vaccinated, the chain of transmission breaks, protecting those who cannot be immunized.

Though the latest figures come from Australia, health experts stress that this is a global concern. Travel and migration mean outbreaks do not remain confined to national borders. Declining vaccination rates in parts of the United States and Europe could set the stage for similar resurgences.

For families worldwide, the lessons are clear: stay up to date on vaccinations, encourage maternal immunization, and understand that diseases once considered “childhood illnesses of the past” can and do return if immunity gaps open.

Australia’s pertussis outbreak is a wake-up call for all of us. With more than 57,000 cases in a single year and rates still climbing, whooping cough has proven it can resurge when vaccination rates slip.

The AMA’s message is urgent but simple: act now. Pregnant women, parents, and caregivers should prioritize immunization to protect both themselves and those too young to be vaccinated. Free vaccines are available, and the science is clear immunization saves lives. As Dr. McMullen put it, “We must not lose sight of the fact that immunisation saves lives.”

whooping cough cases

ama vaccination warning

pertussis outbreak usa

whooping cough vaccine

cdc health alert

rising pertussis cases

protect against whooping cough

Australia is facing its largest whooping cough outbreak in more than three decades, with medical leaders sounding an urgent alarm: vaccination is the only reliable shield. Whooping cough, or pertussis, is not a new disease, but it is making a dramatic comeback. In 2024, more than 57,000 cases were reported across Australia the highest number since 1991. And the wave has not slowed. In South Australia, early 2025 data show over 1,000 infections — more than ten times higher than the same period last year.The national disease surveillance dashboard reports nearly 19,000 cases already in 2025, with hotspots including Queensland, South Australia, and Western Australia’s Kimberley region. Doctors say this is now Australia’s most significant and long-lasting pertussis outbreak in decades.Pertussis is caused by the bacterium Bordetella pertussis. It spreads easily through coughs and sneezes, thriving in close-contact settings such as households and schools. For most adults, it causes weeks of relentless coughing that disrupts sleep, work, and quality of life. But for infants — especially those too young to be vaccinated it can be life-threatening.Newborns can develop severe respiratory distress, pneumonia, and even brain damage from prolonged oxygen deprivation during coughing fits. Globally, the World Health Organization estimates that pertussis kills tens of thousands of children every year, most of them under six months old.AMA’s Urgent CallThe Australian Medical Association (AMA) has issued a clear warning: complacency is dangerous. AMA President Dr. Danielle McMullen described the outbreak as “extremely concerning,” citing both the sheer scale of cases and the drop in vaccination coverage.“We can’t afford to be complacent,” Dr. McMullen said. “Each year, thousands of lives are lost to respiratory diseases like whooping cough — and we all have a role to play in preventing their spread. Vaccination remains our most powerful defence.”Why Pregnancy Vaccination is Crucial?One of the AMA’s strongest messages is directed at expectant mothers. A pertussis-containing vaccine is recommended during every pregnancy, ideally between 20 and 32 weeks. This approach allows protective antibodies to pass from mother to baby through the placenta, shielding the newborn during the critical first weeks of life.“Maternal vaccination creates antibodies which are passed to the unborn baby and protect them in their first days and weeks of life,” Dr. McMullen explained. “But it doesn’t stop there — ensuring family members and other caregivers are also vaccinated helps create a protective cocoon around infants.”This cocooning strategy reduces the risk that parents, grandparents, siblings, or caregivers will transmit the infection to newborns who are too young to complete their first immunization schedule.Vaccines Are Free and AccessibleIn Australia, whooping cough vaccines are free for all pregnant women under the National Immunisation Program. Parents are also encouraged to keep their children’s vaccines up to date, particularly during the first six months, when infants are most vulnerable.For adults, boosters are recommended every 10 years, especially for anyone living with or caring for babies. General practitioners and pharmacies can check vaccination records and provide catch-up doses when needed.Falling Vaccination Rates and Rising CasesPart of what makes this outbreak alarming is its timing. Australia has not met its childhood vaccination targets in several regions, and vaccine hesitancy has crept upward in recent years. This leaves pockets of communities vulnerable, creating fertile ground for pertussis to spread.The AMA warns that failing to address this could undo decades of progress in reducing serious childhood diseases. “Getting vaccinated is one of the simplest and most effective ways you can protect your loved ones and your community,” Dr. McMullen said.Learning From HistoryAustralia has seen waves of whooping cough before. The last major epidemic peaked in 2011 with over 38,000 cases. But today’s surge is different in scale, surpassing even that crisis and persisting longer. Globally, other countries have also seen cyclical rises in pertussis, underscoring that this is not just an Australian problem.The key difference between a contained outbreak and a devastating one is vaccination coverage. Experts point to herd immunity thresholds: when enough people are vaccinated, the chain of transmission breaks, protecting those who cannot be immunized.Though the latest figures come from Australia, health experts stress that this is a global concern. Travel and migration mean outbreaks do not remain confined to national borders. Declining vaccination rates in parts of the United States and Europe could set the stage for similar resurgences.For families worldwide, the lessons are clear: stay up to date on vaccinations, encourage maternal immunization, and understand that diseases once considered “childhood illnesses of the past” can and do return if immunity gaps open.Australia’s pertussis outbreak is a wake-up call for all of us. With more than 57,000 cases in a single year and rates still climbing, whooping cough has proven it can resurge when vaccination rates slip.The AMA’s message is urgent but simple: act now. Pregnant women, parents, and caregivers should prioritize immunization to protect both themselves and those too young to be vaccinated. Free vaccines are available, and the science is clear immunization saves lives. As Dr. McMullen put it, “We must not lose sight of the fact that immunisation saves lives.”

Hard-To-Manage High Blood Pressure Could Now Be Treated With A Pill In Just 12-Weeks

Hard-To-Manage Blood Pressure Could Now Be Treated With A Pill In Just 12-Weeks

Ozempic Rebound: This Is How Quickly You Could Gain Weight After You Quit Ozempic

ozempic rebound: this is how quickly you could gain weight after you quit ozempic

Nicole Eggert Breast Cancer Update: She Shared Her 'Mastectomy With Reconstruction' Amid Cancer Treatment

nicole eggert breast cancer update: she shared her 'mastectomy with reconstruction' amid cancer treatment

Can Diabetes Drugs Steal Your Vision? Why GLP-1s Are Facing Eye Damage Claims

can diabetes drugs steal your vision? why glp-1s are facing eye damage claims

<span>High blood pressure</span>, or hypertension, is one of the most common health problems worldwide yet also one of the most stubborn to control. Despite decades of new drugs and treatment combinations, millions of people remain unable to bring their blood pressure down to safe levels. Now, scientists say they may finally have an answer in the form of a pill that works in just 12 weeks.

More than 1.3 billion people globally are living with hypertension. For about half of them, blood pressure remains uncontrolled, and in roughly one in ten, it’s resistant even to multiple medications. That group faces the highest risk of stroke, heart attack, kidney disease, dementia, and premature death.

In the United States alone, nearly half of adults have elevated blood pressure, according to the CDC. For millions of these patients, lifestyle changes like reducing salt intake, exercising more, or losing weight help — but for many, even combining several prescription drugs is not enough. Resistant hypertension has long been a frustrating challenge for both patients and doctors.

Enter baxdrostat, a new pill developed by AstraZeneca. Early data suggest it may finally offer hope to patients with hard-to-control blood pressure. In a large clinical trial known as BaxHTN, which included 796 patients from 214 clinics worldwide, baxdrostat demonstrated significant blood pressure reductions over just 12 weeks.

Patients who took either 1 mg or 2 mg of the drug daily saw their systolic blood pressure drop by about 9–10 mmHg more than those who received a placebo. For context, cardiologists say that even a 5 mmHg reduction can lower cardiovascular risk significantly. Nearly four in ten patients on baxdrostat reached healthy blood pressure targets — compared with fewer than two in ten on placebo.

Professor Bryan Williams, chair of medicine at University College London and principal investigator of the trial, called the findings “a gamechanger.” He explained, “I’ve never seen blood pressure reductions of this magnitude with a drug in such a challenging patient group. This has the potential to help up to half a billion people worldwide.”

<h2>Why Existing High Blood Pressure Treatments Fall Short?</h2>

To understand why baxdrostat is making headlines, it’s important to look at how blood pressure medications currently work. Most existing drugs target the symptoms of hypertension:

<ul><li>Diuretics help the body eliminate excess fluid and salt.</li><li>Vasodilators relax arteries to reduce resistance.</li><li>ACE inhibitors and ARBs block hormones that constrict blood vessels.</li><li>Calcium channel blockers ease the workload of the heart by limiting calcium uptake.</li></ul>

While effective for many, these medications often fail in resistant hypertension. Patients may cycle through multiple classes of drugs, often taking three or more at once, and still see little improvement. Side effects like dizziness, fatigue, and swelling can make adherence harder.

<h2>How Does The Pill Tackle the Root Cause of Aldosterone?</h2>

Baxdrostat takes a different approach. Instead of targeting blood vessels or fluid directly, it blocks an enzyme critical to producing aldosterone, a hormone made in the adrenal glands.

Aldosterone regulates salt and water balance in the body, but some people produce too much of it. Excess aldosterone pushes the body to retain salt and fluid, raising blood pressure and making it unusually hard to control. Scientists have long known that aldosterone plays a central role in resistant hypertension, but attempts to block its production selectively have fallen short — until now.

Williams called baxdrostat “a triumph of scientific discovery,” noting that the drug’s precision in targeting aldosterone could explain why it worked so effectively in patients who had failed multiple treatments.

<h2>Could These Results Shift Hypertension Guidelines?</h2>

The results of the BaxHTN trial were presented at the European Society of Cardiology Congress in Madrid and published in the New England Journal of Medicine. Cardiologists at the meeting emphasized the potential impact on global treatment guidelines if baxdrostat wins regulatory approval.

Dr. Stacey E. Rosen, volunteer president of the American Heart Association, who was not involved in the trial, noted: “Resistant hypertension is incredibly difficult to manage. Having another option, especially one that directly addresses aldosterone, could be transformative.”

The safety profile of baxdrostat was also encouraging. The most common side effect observed was mild abnormalities in sodium and potassium levels, but these were rare. Unlike some older treatments, baxdrostat did not show widespread adverse effects.

Hypertension is often called the “silent killer” because it produces no obvious symptoms while quietly damaging arteries, the brain, kidneys, and heart. Globally, it contributes to more than 10 million deaths each year, making it the single most important modifiable risk factor for heart disease, the world’s leading cause of death.

Lowering blood pressure is the most effective way to reduce this burden. Studies show that every 10 mmHg reduction in systolic blood pressure cuts the risk of stroke by about 40 percent and heart disease by about 25 percent.

<h2>What Comes Next for High Blood Pressure Patients?</h2>

For patients who have struggled for years to bring their numbers down despite medication, a once-daily pill that directly addresses a root cause could be life-changing.

Historically, hypertension was most common in Western nations. Today, thanks to changes in diet and lifestyle, low- and middle-income countries carry the heaviest burden. More than half of all people with hypertension now live in Asia, including 226 million in China and nearly 200 million in India.

That global spread makes baxdrostat’s potential even more important. If approved, the drug could not only transform care in the United States and Europe but also provide a critical tool in regions where hypertension is rising fastest and healthcare access is uneven.

AstraZeneca is expected to file for regulatory approval soon. If approved, baxdrostat would be the first new type of hypertension drug in decades. Experts caution, however, that more research is needed to understand how the drug performs over longer periods and across diverse populations.

Still, the initial results have generated rare excitement in a field where progress has been incremental for years. For doctors treating resistant hypertension, a 12-week pill that lowers blood pressure by nearly 10 mmHg represents a genuine breakthrough.

As Professor Williams summed it up, “This could change how we treat one of the most important causes of death and disability worldwide. For patients and clinicians alike, that is hugely exciting.”

high blood pressure

blood pressure pill

resistant hypertension treatment

new hypertension drug

manage blood pressure

clinical trial blood pressure

12week hypertension pill

high blood pressure treatment

High blood pressure, or hypertension, is one of the most common health problems worldwide yet also one of the most stubborn to control. Despite decades of new drugs and treatment combinations, millions of people remain unable to bring their blood pressure down to safe levels. Now, scientists say they may finally have an answer in the form of a pill that works in just 12 weeks.More than 1.3 billion people globally are living with hypertension. For about half of them, blood pressure remains uncontrolled, and in roughly one in ten, it’s resistant even to multiple medications. That group faces the highest risk of stroke, heart attack, kidney disease, dementia, and premature death.In the United States alone, nearly half of adults have elevated blood pressure, according to the CDC. For millions of these patients, lifestyle changes like reducing salt intake, exercising more, or losing weight help — but for many, even combining several prescription drugs is not enough. Resistant hypertension has long been a frustrating challenge for both patients and doctors.Enter baxdrostat, a new pill developed by AstraZeneca. Early data suggest it may finally offer hope to patients with hard-to-control blood pressure. In a large clinical trial known as BaxHTN, which included 796 patients from 214 clinics worldwide, baxdrostat demonstrated significant blood pressure reductions over just 12 weeks.Patients who took either 1 mg or 2 mg of the drug daily saw their systolic blood pressure drop by about 9–10 mmHg more than those who received a placebo. For context, cardiologists say that even a 5 mmHg reduction can lower cardiovascular risk significantly. Nearly four in ten patients on baxdrostat reached healthy blood pressure targets — compared with fewer than two in ten on placebo.Professor Bryan Williams, chair of medicine at University College London and principal investigator of the trial, called the findings “a gamechanger.” He explained, “I’ve never seen blood pressure reductions of this magnitude with a drug in such a challenging patient group. This has the potential to help up to half a billion people worldwide.”Why Existing High Blood Pressure Treatments Fall Short?To understand why baxdrostat is making headlines, it’s important to look at how blood pressure medications currently work. Most existing drugs target the symptoms of hypertension:Diuretics help the body eliminate excess fluid and salt.Vasodilators relax arteries to reduce resistance.ACE inhibitors and ARBs block hormones that constrict blood vessels.Calcium channel blockers ease the workload of the heart by limiting calcium uptake.While effective for many, these medications often fail in resistant hypertension. Patients may cycle through multiple classes of drugs, often taking three or more at once, and still see little improvement. Side effects like dizziness, fatigue, and swelling can make adherence harder.How Does The Pill Tackle the Root Cause of Aldosterone?Baxdrostat takes a different approach. Instead of targeting blood vessels or fluid directly, it blocks an enzyme critical to producing aldosterone, a hormone made in the adrenal glands.Aldosterone regulates salt and water balance in the body, but some people produce too much of it. Excess aldosterone pushes the body to retain salt and fluid, raising blood pressure and making it unusually hard to control. Scientists have long known that aldosterone plays a central role in resistant hypertension, but attempts to block its production selectively have fallen short — until now.Williams called baxdrostat “a triumph of scientific discovery,” noting that the drug’s precision in targeting aldosterone could explain why it worked so effectively in patients who had failed multiple treatments.Could These Results Shift Hypertension Guidelines?The results of the BaxHTN trial were presented at the European Society of Cardiology Congress in Madrid and published in the New England Journal of Medicine. Cardiologists at the meeting emphasized the potential impact on global treatment guidelines if baxdrostat wins regulatory approval.Dr. Stacey E. Rosen, volunteer president of the American Heart Association, who was not involved in the trial, noted: “Resistant hypertension is incredibly difficult to manage. Having another option, especially one that directly addresses aldosterone, could be transformative.”The safety profile of baxdrostat was also encouraging. The most common side effect observed was mild abnormalities in sodium and potassium levels, but these were rare. Unlike some older treatments, baxdrostat did not show widespread adverse effects.Hypertension is often called the “silent killer” because it produces no obvious symptoms while quietly damaging arteries, the brain, kidneys, and heart. Globally, it contributes to more than 10 million deaths each year, making it the single most important modifiable risk factor for heart disease, the world’s leading cause of death.Lowering blood pressure is the most effective way to reduce this burden. Studies show that every 10 mmHg reduction in systolic blood pressure cuts the risk of stroke by about 40 percent and heart disease by about 25 percent.What Comes Next for High Blood Pressure Patients?For patients who have struggled for years to bring their numbers down despite medication, a once-daily pill that directly addresses a root cause could be life-changing.Historically, hypertension was most common in Western nations. Today, thanks to changes in diet and lifestyle, low- and middle-income countries carry the heaviest burden. More than half of all people with hypertension now live in Asia, including 226 million in China and nearly 200 million in India.That global spread makes baxdrostat’s potential even more important. If approved, the drug could not only transform care in the United States and Europe but also provide a critical tool in regions where hypertension is rising fastest and healthcare access is uneven.AstraZeneca is expected to file for regulatory approval soon. If approved, baxdrostat would be the first new type of hypertension drug in decades. Experts caution, however, that more research is needed to understand how the drug performs over longer periods and across diverse populations.Still, the initial results have generated rare excitement in a field where progress has been incremental for years. For doctors treating resistant hypertension, a 12-week pill that lowers blood pressure by nearly 10 mmHg represents a genuine breakthrough.As Professor Williams summed it up, “This could change how we treat one of the most important causes of death and disability worldwide. For patients and clinicians alike, that is hugely exciting.”

hard-to-manage blood pressure could now be treated with a pill in just 12-weeks

About Us

Contact Us

Terms & Conditions

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.

Common Heart Attack Pills May Not Be Safe For Women, New Study Shares Warning

Quick Stories

NHS Launches Free Chickenpox Vaccine: How Vaccinations Can Help Keep Kids In School And Reduce Absenteeism

'Act Now To Protect Yourself ', Warns AMA As Whooping Cases Hit Decades-High, Calls For Vaccinations

Hard-To-Manage High Blood Pressure Could Now Be Treated With A Pill In Just 12-Weeks

Health Conditions A-Z

Cardiologist Says He Would Never Buy These 10 Foods 'After 20 Years Of Treating Heart Diseases'

Deadly Flesh-Eating Bacteria Kills Two Oysters Kill Two: Is Climate Change Making Infection Worse?

Common Heart Attack Pills May Not Be Safe For Women, New Study Shares Warning